Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The new coronavirus outbreak has led to a public health emergency of international concern,
putting all health organizations on high alert. As part of the hygienic measures, isolation
and reinforcement cleaning strategies have been followed. It is known that special attention
and efforts should be applied to protect or reduce transmission in susceptible populations,
including the elderly or those with comorbidities.It has also been proposed a semaforization
to classify patients with respiratory symptoms based on: Fever (38ºC or more), dry cough,
headache, dyspnea, joint pain, muscle pain, sore throat, nose discharge, conjunctivitis,
chest pain, diarrhea, anosmia, ageusia.
Nitazoxanide has shown to be effective against several viruses, of both types RNA and DNA,
including other coronavirus that produced the Severe Acute Respiratory Syndrome (SARS) and
the Middle East Respiratory Syndrome (MERS).
Facing the lack of options against COVID-19 outbreaks for example in health workers,
nitazoxanide could contribute to decrease the contagious dissemination of SARS-CoV-2, thus
reducing at the same time the Hospital saturation of patients positive to this virus.